These results suggested that with minimal physiological parameter tuning, the model was able to simulate heterogeneous HER2+ breast cancer phenotypes with differential drug response profiles, thus allowing explainable in silico exploration of different drug combinations to deal with various resistance mechanisms during HER2+ mBC treatments. The gene discussed is ERBB2; the disease is breast cancer.